Blog

Brendon Stiles: We owe it to our patients with EGFR mutations

montefioreeinsteinnow.org

Oct 15, 2024, 12:59

Brendon Stiles: We owe it to our patients with EGFR mutations

Brendon Stiles, Professor and Chief, Thoracic Surgery and Surgical Oncology,

“There are some patients with EGFR mutations who respond to immunotherapy, particularly when combined with chemotherapy or anti-angiogenesis drugs. We owe it to our patients with EGFR mutations to figure out who benefits from these strategies.”

Quoting The Lancet Oncology:

“ICYMI:
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated tumors non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.”

Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis

Authors: Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Prof Wenhua Liang, MDa, Prof Jianxing He.

Brendon Stiles: We owe it to our patients with EGFR mutations

anti-angiogenesis drugs Brendon Stiles cancer Cancer research chemotherapy EGFR Mutations Fan Ge Hengrui Liang Hongsheng Deng immunotherapy Jianqi Zheng Jianxing He Montefiore Health System non small cell lung cancer OncoDaily Oncology Qi Cai Shen Lao The Lancet Oncology Wei Wang Wenhua Liang Yi Zhao Ying Chen Ying He Yuan Zhang Zisheng Chen

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage